Skip to main content
OPKO Health Inc. logo

OPKO Health Inc. — Investor Relations & Filings

Ticker · OPK ISIN · US68375N1037 LEI · 529900A4S2D4OGOJLL02 TA Human health and social work activities
Open in API
Filings indexed 3,780 across all filing types
Latest filing 2024-07-28 Regulatory Filings
Country US United States of America
Listing TA OPK

About OPKO Health Inc.

https://www.opko.com

OPKO Health, Inc. is a fully-integrated healthcare company operating in both pharmaceuticals and diagnostics. Its pharmaceutical division develops and commercializes novel therapies for serious diseases. Key marketed products include NGENLA™, a long-acting treatment for pediatric growth hormone deficiency partnered with Pfizer, and RAYALDEE®. The company's research focuses on advancing multispecific therapies for cancers and infectious diseases. Through its subsidiary, BioReference Laboratories, OPKO operates one of the largest full-service clinical reference laboratories in the U.S., providing comprehensive diagnostic testing services to millions of patients annually.

Recent filings

Filing Released Lang Actions
Updating the company's holdings in GeneDx Holdings, Corp
Regulatory Filings Classification · 95% confidence The document explicitly mentions 'SCHEDULE 13D/A' and refers to the reporting entity as a 'foreign private issuer as defined by U.S. Securities Laws.' Schedule 13D/A is an amendment to a Schedule 13D filing, which reports beneficial ownership of more than 5% of a class of a company's securities. This type of filing relates to significant share ownership changes or acquisitions. Among the provided codes, 'MRQ' (Major Shareholding Notification) is the closest fit for reporting significant ownership changes, although Schedule 13D is a specific US SEC filing type. Given the context of reporting significant ownership (Schedule 13D/A) and the presence of Israeli regulatory headers (Israel Securities Authority, Tel Aviv Stock Exchange), this is a regulatory filing concerning shareholding. Since 'MRQ' covers 'Notification of changes in significant share ownership levels (crossing thresholds),' it is the most appropriate classification, even though the specific form is US-based. The document is a direct filing/report, not an announcement of a report.
2024-07-28 English
Updating the company's holdings in GeneDx Holdings, Corp
Director's Dealing Classification · 100% confidence The document explicitly begins with "FORM 4" and contains the header "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES". Form 4 is the standard SEC filing used to report changes in beneficial ownership of securities by insiders (directors, officers, or 10% owners). This directly corresponds to reporting personal share transactions by company directors and executives, which is categorized as Director's Dealing (DIRS) in the provided definitions. Although the definition for DIRS is 'Report of personal share transactions by company directors and executives (insider trades)', the SEC Form 4 is the specific regulatory document for this activity.
2024-07-24 English
Updating the company's holdings in GeneDx Holdings, Corp
Report Publication Announcement Classification · 98% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). The content explicitly states: 'Attached hereto is a report on *interested party transaction* *20240424Form4_isa.pdf*'. This structure—a brief announcement stating that a specific report (in this case, related to an interested party transaction, which often falls under insider/related party disclosures) is attached or published—fits the definition of a Report Publication Announcement (RPA). It is not the full transaction report itself, but the notification of its release. The document length is very short (1768 chars), supporting the RPA classification over a comprehensive report like 10-K or IR.
2024-07-24 English
Updating the company's holdings in GeneDx Holdings, Corp
Director's Dealing Classification · 99% confidence The document explicitly contains the header "FORM 4" and is titled "STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES". It details transactions (Acquired/Disposed of) by a Reporting Person (Steven D. Rubin) concerning OPKO Health, Inc. / GeneDx Holdings Corp. stock. Form 4 filings are mandatory reports for insiders (directors, officers, 10% owners) detailing personal share transactions. This specific type of filing is not explicitly listed in the provided definitions (AGM-R, 10-K, AR, etc.). However, the closest functional category among the choices that deals with insider trading/executive transactions is 'Director's Dealing' (DIRS), which covers personal share transactions by directors and executives. Although Form 4 is a specific SEC filing, DIRS is the most appropriate thematic match for insider transaction reporting.
2024-07-21 English
Updating the company's holdings in GeneDx Holdings, Corp
Report Publication Announcement Classification · 98% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). The content explicitly states: 'Attached hereto is a report on *interested party transaction* *20240721Form4_isa.pdf*'. This structure—a brief announcement stating that a specific report (in this case, related to an interested party transaction, which often falls under insider/related party disclosures) is attached or published—fits the definition of a Report Publication Announcement (RPA). It is not the full transaction report itself, but the notification of its release. Given the context of related party transactions and the short length (1768 chars), RPA is the most appropriate classification, as it announces the publication of another document.
2024-07-21 English
Announces $100 Million Share Repurchase Program
Transaction in Own Shares Classification · 100% confidence The document is a press release titled "OPKO Health Announces $100 Million Share Repurchase Program." The core subject is the authorization by the Board of Directors for the company to buy back its own common stock. This action directly relates to the company's capital structure management, specifically the reduction of outstanding shares through open market purchases or accelerated share repurchase transactions. According to the definitions, 'Transaction in Own Shares (Code: POS)' covers 'Report of the company buying back or selling its own shares (share repurchase/issuance).' While 'Capital/Financing Update (CAP)' is related, POS is more specific to share repurchases. Given the explicit announcement of a share repurchase program, POS is the most accurate classification.
2024-07-18 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.